Goldman Sachs Group Inc Glycomimetics Inc Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Glycomimetics Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,114,708 shares of GLYC stock, worth $367,853. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,114,708
Previous 919,355
21.25%
Holding current value
$367,853
Previous $2.17 Million
54.17%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding GLYC
# of Institutions
81Shares Held
36.8MCall Options Held
969KPut Options Held
636K-
Bvf Inc San Francisco, CA9.54MShares$3.15 Million0.86% of portfolio
-
Artal Group S.A. Luxembourg, N48.59MShares$2.83 Million1.39% of portfolio
-
Nea Management Company, LLC Timonium, MD3.84MShares$1.27 Million0.81% of portfolio
-
Octagon Capital Advisors LP New York, NY3MShares$990,0001.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.76MShares$911,4530.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $17.3M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...